205 related articles for article (PubMed ID: 37182176)
1. The cost-effectiveness analysis of serplulimab versus regorafenib for treating previously treated unresectable or metastatic microsatellite instability-high or deficient mismatch repair colorectal cancer in China.
Ma Y; Zhou J; Ye Y; Wang X; Ma A; Li H
Front Oncol; 2023; 13():1113346. PubMed ID: 37182176
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States.
Aguiar-Ibáñez R; Hardern C; van Hees F; Lee D; Patel A; Chhabra N; Baluni G; Amonkar M; Lai Y; Xu R; Massaad R; Fogelman D
J Med Econ; 2022; 25(1):469-480. PubMed ID: 35184650
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system.
Zhu C; Han G; Wu B
BMC Health Serv Res; 2023 Oct; 23(1):1083. PubMed ID: 37821934
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China.
Guan X; Li H; Xiong X; Peng C; Wang N; Ma X; Ma A
J Med Econ; 2021; 24(1):339-344. PubMed ID: 33571036
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China.
Liu S; Jiang N; Dou L; Li S
Front Immunol; 2023; 14():1172242. PubMed ID: 37215110
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of serplulimab in combination with cisplatin plus 5-fluorouracil chemotherapy compared to cisplatin plus 5-fluorouracil chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.
Lin YT; Zhou CC; Xu K; Zhang MD; Li X
Ther Adv Med Oncol; 2023; 15():17588359231213621. PubMed ID: 38028139
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer.
Thurgar E; Gouldson M; Matthijsse S; Amonkar M; Marinello P; Upadhyay N; Nwankwo C; Aguiar-Ibáñez R
J Med Econ; 2021; 24(1):675-688. PubMed ID: 33866938
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of analysis serplulimab plus chemotherapy as first-line therapy for PD-L1-positive advanced esophageal squamous cell carcinoma.
Zheng H; Li J; Wen F; Su N
Front Oncol; 2023; 13():1216960. PubMed ID: 38023250
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer.
Liang X; Chen X; Li H; Li Y
Front Public Health; 2023; 11():1156427. PubMed ID: 37727602
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of additional serplulimab to chemotherapy in metastatic squamous non-small cell lung cancer patients.
Zheng H; Zeng Y; Wen F; Hu M
Front Immunol; 2024; 15():1382088. PubMed ID: 38711525
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China.
Xiang G; Jiang T; Gan L; Wu Y; Zhang N; Xing H; Su H; Li Y; Peng D; Ni R; Liu Y
Front Immunol; 2023; 14():1223020. PubMed ID: 37720211
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States.
Cho SK; Hay JW; Barzi A
Clin Colorectal Cancer; 2018 Dec; 17(4):e751-e761. PubMed ID: 30228027
[TBL] [Abstract][Full Text] [Related]
13. Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis.
Zhu Y; Liu K; Qin Q; Zhu H
Front Immunol; 2022; 13():1044678. PubMed ID: 36685541
[TBL] [Abstract][Full Text] [Related]
14. Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing.
Shao T; Zhao M; Liang L; Tang W
BioDrugs; 2023 May; 37(3):421-432. PubMed ID: 36840914
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of serplulimab plus chemotherapy as the first-line treatment of oesophageal squamous cell carcinoma in China.
Chen F; Long Y; Yang J; Zhong K; Liu B
BMJ Open; 2023 Dec; 13(12):e078924. PubMed ID: 38149425
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer.
Liu T; Liu S; Guan S; Tai Y; Jin Y; Dong M
J Chemother; 2023 Dec; 35(8):745-752. PubMed ID: 36591729
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of serplulimab combined with chemotherapy in the treatment of extensive-stage small-cell lung cancer from the perspective of the healthcare system in China.
Long Y; Xu Y; Liao L; Zhou Y; Wang H
BMJ Open; 2023 Aug; 13(8):e072106. PubMed ID: 37586861
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of serplulimab combination therapy versus chemotherapy alone for patients with extensive-stage small cell lung cancer.
Zheng Z; Chen H; Cai H
Front Oncol; 2023; 13():1259574. PubMed ID: 38282674
[TBL] [Abstract][Full Text] [Related]
19. A cost-effectiveness analysis of the combination of serplulimab with chemotherapy for advanced esophageal squamous cell carcinoma: insights from the ASTRUM-007 trial.
Li J; Xu C; Yuan S
Cost Eff Resour Alloc; 2024 Jan; 22(1):8. PubMed ID: 38281053
[TBL] [Abstract][Full Text] [Related]
20. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]